The National Authority for Medicines and Health Products (Infarmed) has announced a voluntary recall of a batch of the antidepressant medication Paroxetine toLife 20 mg.
In an informative circular, Infarmed explained that Towa Pharmaceutical, S.A. will carry out the voluntary recall of the batch specified below of Paroxetine toLife 20 mg, film-coated tablets, 60 units, after an analytical result above acceptable limits for an impurity was detected.
Consequently, the authority has mandated “the immediate suspension of the sale of this batch,” indicating that “entities holding stock of this medication batch are prohibited from selling, dispensing, or administering it and should proceed with its return.”
They further advise that “patients using medication from this batch should not interrupt their treatment.” However, they should “contact their doctor as soon as possible to assess whether a replacement with an alternative medication is necessary.”
